Sarepta Therapeutics Inc’s recently made public that its Director Nicaise Claude unloaded Company’s shares for reported $0.25 million on Mar 12 ’25. In the deal valued at $99.64 per share,2,491 shares were sold. As a result of this transaction, Nicaise Claude now holds 27,812 shares worth roughly $1.01 million.
Then, Nicaise Claude bought 2,491 shares, generating $248,226 in total proceeds.
Before that, Wigzell Hans Lennart Rudolf sold 10,500 shares. Sarepta Therapeutics Inc shares valued at $1,310,820 were divested by the Director at a price of $124.84 per share. As a result of the transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares, worth roughly $0.83 million.
Evercore ISI downgraded its Sarepta Therapeutics Inc [SRPT] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. H.C. Wainwright also remained covering SRPT and has increased its forecast on April 02, 2025 with a “Neutral” recommendation from previously “Sell” rating. RBC Capital Mkts revised its rating on March 31, 2025. It rated SRPT as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of SRPT
On Tuesday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock fall -0.47% to $36.20. Over the last five days, the stock has lost -22.57%. Sarepta Therapeutics Inc shares have fallen nearly -70.23% since the year began. Nevertheless, the stocks have fallen -72.64% over the past one year. While a 52-week high of $173.25 was reached on 01/07/25, a 52-week low of $35.46 was recorded on 05/13/25. SMA at 50 days reached $67.18, while 200 days put it at $109.62.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 34.96, which if violated will result in even more drops to 33.72. On the upside, there is a resistance level at 37.38. A further resistance level may holdings at 38.56. The Relative Strength Index (RSI) on the 14-day chart is 22.77, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -15.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.65%. Stochastics %K at 3.40% indicates the stock is a buying.
The most recent change occurred on February 11, 2025 when Deutsche Bank began covering the stock and recommended ‘”a Hold”‘ rating along with a $136 price target.
